Trial Profile

A phase I, placebo controlled, dose escalation safety and pharmacokinetic study of (Z)-Endoxifen in healthy female volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endoxifen (Primary) ; Endoxifen (Primary)
Indications Breast cancer
Focus Adverse reactions
Sponsors Atossa Genetics; Atossa Therapeutics

Most Recent Events

01 Feb 2018 Additional findings from the oral arm of the Endoxifen of this study presented in an Atossa Genetics Media Release.
31 Jan 2018 According to a Atossa Genetics media release, additional data from the study will be disscused on a conference call in Feb 2018.
25 Oct 2017 According to a Atossa Genetics media release, company will host a conference call to discuss preliminary results from oral Endoxifen arm on 25 Oct 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com